Sign In
Buy ALPMY
$13.40
-0.200 (-1.47%)
At Close: Jun 03, 2026
Astellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Up 294.1% in December
04:37am, Thursday, 25'th Dec 2025
Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) was the recipient of a large growth in short interest during the month of December. As of December 15th, there was short interest totaling 63,309
Autobahn Labs Forms Strategic Partnership with Astellas to Accelerate Academic Discoveries into New Medicines
07:30am, Thursday, 11'th Dec 2025
PALO ALTO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Autobahn Labs (“Autobahn”), a venture studio focused on transforming high-potential academic science into investable drug discovery and develop
Astellas to Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio at 2026 ASCO GI Cancers Symposium
06:30pm, Wednesday, 10'th Dec 2025
- Data reflect new insights and precision oncology advancements in portfolio and pipeline - - Cohort results from Phase 2 ILUSTRO study evaluating a zolbetuximab triplet combination regimen in first-l
Astellas To Present New Data on XOSPATA™ (gilteritinib) Across the FLT3m+ AML Disease Continuum at ASH 2025 Annual Meeting
08:00am, Friday, 05'th Dec 2025
- Presentations include pooled post-hoc analysis of the Phase 3 ADMIRAL and COMMODORE data on post-transplant gilteritinib resumption in relapsed or refractory FLT3m+ AML - - Findings from the Phase 3
Babs is sharing her family's history with progressive retinal disease GA, the advanced form of dry age-related macular degeneration (AMD), is a serious condition that may lead to irreversible vision l
Astellas Presents Preliminary Real-World VEOZAH™ (fezolinetant) Data From OPTION-VMS Phase IV Observational Study
08:00am, Wednesday, 22'nd Oct 2025
Extensive and growing evidence continues to reinforce fezolinetant as an effective treatment for moderate to severe VMS associated with menopause Preliminary analysis from OPTION-VMS observational stu
Astellas-Pfizer's combination therapy halves risk of death in bladder cancer patients
10:37am, Saturday, 18'th Oct 2025
Pfizer and Japanese firm Astellas' drug Padcev, combined with Merck's Keytruda, lowered the risk of tumor recurrence, progression or death in patients suffering from a type of bladder cancer, the comp
Pfizer, Merck And Astellas Have An 'Enormous New Hope' For Bladder Cancer Patients
10:30am, Saturday, 18'th Oct 2025
Pharma titans Merck, Pfizer and Astellas Pharma are delivering an "enormous new hope" for patients with an aggressive form of bladder cancer.
Astellas to Present First Real-World VEOZAH™ (fezolinetant) Data at 2025 Annual Meeting of The Menopause Society
08:00pm, Tuesday, 14'th Oct 2025
TOKYO , Oct. 14, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that VEOZAH™ (fezolinetant), its first-in-class, targeted, non
Astellas to Present New Data on IZERVAY™ (avacincaptad pegol intravitreal solution) in Geographic Atrophy at AAO 2025 Annual Meeting
07:30pm, Wednesday, 08'th Oct 2025
Presentations include long-term GATHER2 open-label extension data, real-world treatment patterns on safety, and biomarker insights on geographic atrophy disease progression TOKYO , Oct. 8, 2025 /PRNew
Astellas Announces Top Management Personnel Change
02:00am, Monday, 29'th Sep 2025
TOKYO , Sept. 29, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the following changes to its Top Management structure, effectiv
Astellas Announces a Partnership with the "Korea Institute of Startup and Entrepreneurship Development", an Umbrella Organization of the "Ministry of SMEs and Startups", a Korean Government Agency, for the Operation of the "Partnership with Global Companies Program"
12:00am, Thursday, 17'th Jul 2025
- Supporting Korean Startups' Drug Discovery Research and Global Expansion - - First Pharmaceutical Company from Japan to Actively Support the Operation of the Program - TOKYO , July 17, 2025 /PRNews
Is Alpha Cognition Inc. (ACOG) Outperforming Other Medical Stocks This Year?
10:41am, Tuesday, 01'st Jul 2025
Here is how Alpha Cognition Inc. (ACOG) and Astellas Pharma Inc. (ALPMY) have performed compared to their sector so far this year.
Mitsubishi Research Institute and Astellas Announce Collaboration to Support Pharma Startups in Japan
01:10am, Friday, 13'th Jun 2025
Accelerating the Growth of Globally Active Drug-Discovery Startups from Japan TOKYO , June 13, 2025 /PRNewswire/ -- Mitsubishi Research Institute, Inc. ("MRI") and Astellas Pharma Inc. ("Astellas") to
Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year?
10:46am, Thursday, 12'th Jun 2025
Here is how Astellas Pharma Inc. (ALPMY) and AtriCure (ATRC) have performed compared to their sector so far this year.
